Immuneering Corporation (IMRX) Free cash flow 2020–2025
Immuneering Corporation (IMRX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$45.5MFY2025 · since FY2020: -$14.7M → -$45.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$45.5M | +17.4% |
| FY2024 | -$55.1M | -11.7% |
| FY2023 | -$49.3M | -10.0% |
| FY2022 | -$44.8M | -45.1% |
| FY2021 | -$30.9M | -110.7% |
| FY2020 | -$14.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice